# Nuo Therapeutics, Inc. (AURX) · Edgar & Edgarette company card

> Nuo Therapeutics (AURX) grew revenue 143% in FY2025 to $3 million, operating margin -76.0% against a 1.2% median for surgical & medical instruments & apparatus, equity -51.8% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1091596 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/AURX) · [JSON](https://www.pops4.com/boards/company/AURX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $3M |
| Revenue growth, 1 year | 142.7% |
| Revenue growth per year | — |
| Operating margin | -76.0% (prior year -180.0%) |
| Net margin | -75.8% |
| Operating cash flow | −$864,971 |
| Capital spending | $274,756 |
| Free cash flow | −$1M |
| Cash | $548,946 |
| Long-term debt | — |
| Total assets | $2M |
| Total equity | −$956,559 |
| Equity ÷ assets | -51.8% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -70.68 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -5.73 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -76.0% in FY2025; revenue is hard to predict: its 80% range is ±47%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $3.3M (FY2025). Experience: revenue up 142.7% on the year; operating margin -76.0%, up from -180.0%. Soundness: equity -51.8% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $5.4M and $14.9M next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $5.0M to $16.0M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -76.0% against a 1.2% median; growth 142.7% against 11.6%.

Range logged 2026-10-07, receipt 51ddad1a89a33f6b, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-11-17 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1091596/000143774926037320/0001437749-26-037320-index.htm)
- 10-Q · filed 2026-11-13 · [filing](https://www.sec.gov/Archives/edgar/data/1091596/000143774926036956/0001437749-26-036956-index.htm)
- 8-K · filed 2026-10-06 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1091596/000143774926032242/0001437749-26-032242-index.htm)
- 8-K · filed 2026-08-17 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1091596/000143774926028109/0001437749-26-028109-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1091596/000143774926028053/0001437749-26-028053-index.htm)
- 8-K · filed 2026-06-03 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1091596/000143774926019199/0001437749-26-019199-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001091596.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1091596

## Cite

POPS4, Edgar & Edgarette: Nuo Therapeutics, Inc. (AURX) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/AURX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

